oral orexin positive modulator / Centessa - LARVOL DELTA

Sosei Heptares spin-off company Orexia Therapeutics merged into newly created Centessa Pharmaceuticals (PRNewswire) - "Sosei Group Corporation…notes the announcement today from Centessa Pharmaceuticals…about its launch as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs….Centessa has completed the merger of 10 private biotech companies (‘Centessa Subsidiaries’) that will each continue to develop its assets with oversight from the Centessa management team….Raised $250 million in an oversubscribed Series A financing from a group of blue-chip investors….Orexia is developing oral and intranasal orexin receptor agonists..."

Financing • M&A • CNS Disorders • Narcolepsy • Sleep Disorder

Sosei Heptares announces Medicxi to invest up to €40 million in new collaboration based on its orexin agonist program (PRNewswire) - "Under the terms of the agreement, Orexia and Inexia will obtain a portfolio of related patents from the Company[2] and have the rights to exploit a series of Orexin OX1 and OX2 positive modulators and products derived therefrom, including dual OX1/OX2 agonists, designed and developed by the Company...Specific target indications will be determined as the programs advance, and will include narcolepsy, a rare sleep disorder."

Financing